Skip to Main Content

DBV Technologies is withdrawing its marketing application for a peanut allergy therapy following discussions with the Food and Drug Administration, the company said Wednesday.

Based on feedback from regulators, DBV concluded that its submission lacked “sufficient detail regarding data on manufacturing procedures and quality controls.” The company believes it can re-file with the FDA without having to conduct any additional clinical trials, although when that will happen was not made clear.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • please, explain to me, how a company can lure the FDA to approve what is nothing more than fat free peanut flour, that you can buy at any grocery shop, as a pricey “therapeutic” drug

    my only explanation is bribing

Comments are closed.